Alnylam begins Phase I study of blood disorder drug

US-based Alnylam Pharmaceuticals has started a Phase I trial with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting antithrombin (AT), for the treatment of hemophilia and rare bleeding disorders (RBD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news